SCHEMBL6490372

SCHEMBL6490372

Nc1ccc2c(c1)CN(C(=O)Cc1ccccc1)C2

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.58
NPC1 O15118 2/20 0.52
KMT2A Q03164 2/20 0.52
RAB9A P51151 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
HSD11B1 P28845 1/20 0.46
NAMPT P43490 1/20 0.45
ROCK1 Q13464 3/20 0.45
ROCK2 O75116 1/20 0.45
HDAC8 Q9BY41 3/20 0.44
MEN1 O00255 1/20 0.44
HSD17B3 P37058 1/20 0.44
TMPRSS2 O15393 1/20 0.44
USP2 O75604 1/20 0.43
GAA P10253 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TSHR P16473 1/20 0.43
EP300 Q09472 1/20 0.43
CARM1 Q86X55 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19339309 0.82 NAMPT (0.60) HDAC1NPC1KMT2ARAB9AL3MBTL1
SCHEMBL6974709 0.82 NPC1 (0.57) NPC1KMT2ARAB9AROCK1ROCK2
SCHEMBL6643066 0.80 CNR1 (0.46) HDAC1NPC1RAB9AL3MBTL1NAMPT
SCHEMBL1506610 0.79 TMEM97 (0.63) NPC1KMT2ARAB9AMEN1
SCHEMBL1393814 0.77 NR1H2 (0.50) KMT2ANAMPTHDAC8MEN1HSD17B3
SCHEMBL6399884 0.76 PTPN2 (0.55) HDAC1NPC1KMT2AMEN1GAA
SCHEMBL6970730 0.76 NPC1 (0.53) NPC1KMT2ARAB9AL3MBTL1HSD11B1
SCHEMBL6965569 0.76 NPC1 (0.53) NPC1KMT2ARAB9AHSD11B1HDAC8
SCHEMBL6961304 0.76 ALDH1A1 (0.53) HDAC1NPC1KMT2AMEN1TMPRSS2
SCHEMBL6968137 0.76 NPC1 (0.53) NPC1KMT2ARAB9AROCK2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
US-20040133008-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 US disclosed
WO-2004039795-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-13 WO disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040133008-A1 Amide compounds APOB, APOL1, LDLR HDAC1 79/4885NPC1 34/4885KMT2A 916/4885
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 HDAC1 98/4885NPC1 100/4885KMT2A 573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.